<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id>
    <journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id>
    <journal-title-group>
      <journal-title>Orphanet Journal of Rare Diseases</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1750-1172</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7590677</article-id>
    <article-id pub-id-type="publisher-id">1591</article-id>
    <article-id pub-id-type="doi">10.1186/s13023-020-01591-6</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Design, development and deployment of a web-based interoperable registry for inherited retinal dystrophies in Portugal: the IRD-PT</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1014-0483</contrib-id>
        <name>
          <surname>Marques</surname>
          <given-names>João Pedro</given-names>
        </name>
        <address>
          <email>marquesjoaopedro@gmail.com</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Carvalho</surname>
          <given-names>Ana Luísa</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Henriques</surname>
          <given-names>José</given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">6</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Murta</surname>
          <given-names>Joaquim Neto</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Saraiva</surname>
          <given-names>Jorge</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
        <xref ref-type="aff" rid="Aff4">4</xref>
        <xref ref-type="aff" rid="Aff7">7</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Silva</surname>
          <given-names>Rufino</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.28911.33</institution-id><institution-id institution-id-type="ISNI">0000000106861985</institution-id><institution>Ophthalmology Unit, Centro de Responsabilidade Integrado em Oftalmologia (CRIO), </institution><institution>Centro Hospitalar e Universitário de Coimbra (CHUC), </institution></institution-wrap>Praceta Prof. Mota Pinto, 3000-075 Coimbra, Portugal </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>University Clinic of Ophthalmology, Faculty of Medicine, </institution><institution>University of Coimbra (FMUC), </institution></institution-wrap>Coimbra, Portugal </aff>
      <aff id="Aff3"><label>3</label>Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.28911.33</institution-id><institution-id institution-id-type="ISNI">0000000106861985</institution-id><institution>Medical Genetics Unit, </institution><institution>Centro Hospitalar e Universitário de Coimbra (CHUC), </institution></institution-wrap>Coimbra, Portugal </aff>
      <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>University Clinic of Medical Genetics, Faculty of Medicine, </institution><institution>University of Coimbra (FMUC), </institution></institution-wrap>Coimbra, Portugal </aff>
      <aff id="Aff6"><label>6</label>Instituto de Oftalmologia Dr. Gama Pinto (IOGP), Lisbon, Portugal </aff>
      <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>University Clinic of Pediatrics, Faculty of Medicine, </institution><institution>University of Coimbra (FMUC), </institution></institution-wrap>Coimbra, Portugal </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>27</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>27</day>
      <month>10</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2020</year>
    </pub-date>
    <volume>15</volume>
    <elocation-id>304</elocation-id>
    <history>
      <date date-type="received">
        <day>15</day>
        <month>5</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>10</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">The development of multicenter patient registries promotes the generation of scientific knowledge by using real-world data. A country-wide, web-based registry for inherited retinal dystrophies (IRDs) empowers patients and community organizations, while supporting formal partnerships research. We aim to describe the design, development and deployment of a country-wide, with investigators and stakeholders in the global aim to develop high-value, high-utility web-based, user-friendly and interoperable registry for IRDs—the IRD-PT.
</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par2">The IRD-PT is a clinical/genetic research registry included in the <italic>retina.pt</italic> platform (<ext-link ext-link-type="uri" xlink:href="https://www.retina.com.pt">https://www.retina.com.pt</ext-link>), which was developed by the Portuguese Retina Study Group. The <italic>retina.pt</italic> platform collects data on individuals diagnosed with retinal diseases, from several sites across Portugal, with over 1800 participants and over 30,000 consultations to date. The IRD-PT module interacts with the <italic>retina.pt</italic> core system which provides a range of basic functions for patient data management, while the IRD-PT module allows data capture for the specific purpose of IRDs. All IRDs are coded accordingly to the International Statistical Classification of Diseases and Related Health Problems (ICD) 9, ICD 10, ICD 11, and Orphanet Rare Disease Ontology (ORPHA codes) to make the IRD-PT interoperable with other IRD registries across the world. Furthermore, the genes are coded according to the Ontology of Genes and Genomes and Online Mendelian Inheritance in Man, whereas signs and symptoms are coded according to the Human Phenotype Ontology. The IRD-PT module pre-launched at <italic>Centro Hospitalar e Universitário de Coimbra</italic>, the largest reference center for IRDs in Portugal. As of April 1st 2020, finalized data from 537 participants were available for this preliminary analysis.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p id="Par3">In the specific field of rare diseases, the use of registries increases research accessibility for individuals, while providing clinicians/investigators with a coherent data ecosystem necessary to boost research. Appropriate design and implementation of patient registries enables rapid decision making and ongoing data mining, ultimately leading to improved patient outcomes. We have described here the principles behind the design, development and deployment of a web-based, user-friendly and interoperable software tool aimed to generate important knowledge and collecting high-quality data on the epidemiology, genomic landscape and natural history of IRDs in Portugal.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Inherited retinal dystrophies</kwd>
      <kwd>Registry</kwd>
      <kwd>Rare diseases</kwd>
      <kwd>Interoperability</kwd>
      <kwd>Software</kwd>
      <kwd>Data management</kwd>
      <kwd>Research</kwd>
      <kwd>Epidemiology</kwd>
      <kwd>Natural history</kwd>
      <kwd>Clinical genetics</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Novartis (PT)</institution>
        </funding-source>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Sociedade Portuguesa de Oftalmologia (PT)</institution>
        </funding-source>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2020</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par4">The Agency for Healthcare Research and Quality defines a registry as “an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes” [<xref ref-type="bibr" rid="CR1">1</xref>]. Clinical registries have existed for decades in the field of ophthalmology [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR5">5</xref>], serving a variety of purposes, which include (1) capturing the epidemiologic features of an ocular disease or condition, (2) tracking outcomes and complications of drugs or procedures, (3) recording adverse events, or (4) combinations of the above [<xref ref-type="bibr" rid="CR6">6</xref>]. In recent years, policy makers started recognizing clinical registries as an important tool for improving the value of healthcare. Outcome data is now used to fill in gaps of evidence that cannot be provided by randomized controlled trials [<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, data from clinical registries is also increasingly being used to facilitate learning networks and to establish research collaborations between scientific researchers, clinicians, industry, regulators, patient organizations, patients and families [<xref ref-type="bibr" rid="CR7">7</xref>]. This is especially true for rare diseases where the small number of cases for each disease creates additional barriers in the translational research pathway, and makes identification and establishment of a substantial cohort a very difficult task.</p>
    <p id="Par5">Inherited retinal dystrophies (IRDs) are a clinically and genetically heterogenous group of diseases with an estimated prevalence of 1 in 3000 individuals [<xref ref-type="bibr" rid="CR8">8</xref>]. Despite some common ground, genetic profiles vary considerably among regions and ethnic groups [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR16">16</xref>], thus highlighting the importance of obtaining reference population-based data. The presence of founder mutations may greatly contribute for these differences, as observed in a large Israeli population [<xref ref-type="bibr" rid="CR9">9</xref>]. While local hospital-based registries may provide high quality information and resources, their coverage is usually small. To fully understand the prevalence and genomic landscape of IRDs, we must connect knowledge that is widespread throughout miscellaneous registries. The development of multicenter patient registries and natural history studies promote the generation of scientific knowledge by using real-world data. As rare diseases gain visibility as a public health priority and the marketplace expands, acknowledgement of the importance of building collaborative relationships in rare disease research increases [<xref ref-type="bibr" rid="CR7">7</xref>]. A national, web-based registry for IRDs is able to empower patients and community organizations, while supporting formal partnerships with investigators and stakeholders in the global aim to develop high-value, high-utility research.</p>
    <p id="Par6">When developing a registry, it is essential to ensure that it is ethically governed, user-friendly and designed with maximum sustainability. This includes the implementation of foundational, structural, semantic, and organizational interoperability processes to optimize the utility of data and allow its linkage to other existing or future registries [<xref ref-type="bibr" rid="CR7">7</xref>]. By making data computationally accessible, it is possible to bridge compatibility gaps between different hospitals, healthcare systems, registries and languages [<xref ref-type="bibr" rid="CR17">17</xref>]. Adoption of comprehensive phenotype and rare disease ontologies enables this type of sharing by making data findable, accessible, interoperable, and re-usable (FAIR principles) [<xref ref-type="bibr" rid="CR18">18</xref>]. These features have made Orphanet Rare Disease Ontology (ORDO) a standard for rare disease coding in European health-care systems and led to the widespread adoption of ontologies like the Human Phenotype Ontology (HPO) by global genomics initiatives, like the European Reference Network for Rare Eye Disease (ERN-EYE) [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
    <p id="Par7">The purpose of this study is to describe the design, development and deployment of a country-wide, web-based, user-friendly and interoperable registry for IRDs—the IRD-PT.</p>
  </sec>
  <sec id="Sec2">
    <title>Results</title>
    <sec id="Sec3">
      <title>Data capture</title>
      <p id="Par8">The IRD-PT was designed to capture longitudinal data on IRDs. The data captured by the IRD-PT module is kept to a minimum to deliver an efficient and user-friendly data collecting tool. The user must complete all the mandatory fields/check all the mandatory boxes in order to save the entry. However, the system allows editing and/or completion of previously unanswered non-mandatory fields at the user’s convenience. The list of covered clinical diagnoses is shown on Table <xref rid="Tab1" ref-type="table">1</xref>, while the list of the genes and their respective Ontology of Genes and Genomes (OGG) and Mendelian Inheritance in Man (MIM) numbers are shown on Table <xref rid="Tab2" ref-type="table">2</xref>. Even though inherited optic neuropathies and other genetically-associated retinal diseases (such as Pseudoxanthoma Elasticum-associated retinopathy or isolated foveal hypoplasia) are not IRDs per se, we opted to include them in the registry since these are common diagnoses in an Ophthalmic Genetics clinic. This is not something previously unseen. In fact, these diseases are also part of the Inherited Retinal Disease Classification proposed by Stone et al. [<xref ref-type="bibr" rid="CR16">16</xref>].
<table-wrap id="Tab1"><label>Table 1</label><caption><p>List and ORPHA numbers of the clinical diagnoses covered by the IRD-PT module</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Inherited retinal dystrophies<sup>a</sup></th><th align="left"/></tr><tr><th align="left"/><th align="left">ORPHA 71862</th><th align="left"/></tr></thead><tbody><tr><td align="left"><bold>1. ISOLATED PROGRESSIVE INHERITED RETINAL DISORDER (ORPHA 519306)</bold></td><td align="left"><bold>3. SYNDROMIC INHERITED RETINAL DISORDER (ORPHA 519325)</bold></td><td align="left"><bold>5. CHORIORETINAL DYSTROPHIES (ORPHA 519,300)</bold></td></tr><tr><td align="left">1.1 Retinitis punctata albescens (ORPHA 52427)</td><td align="left">3.1. Alström syndrome (ORPHA 64)</td><td align="left">5.1. Bietti crystalline dystrophy (ORPHA 41751)</td></tr><tr><td align="left">1.2. ARB (ORPHA 139455)</td><td align="left">3.2. Jalili syndrome (ORPHA 1873)</td><td align="left">5.2. CACD (ORPHA 75377)</td></tr><tr><td align="left">1.3. Cone/cone-rod dystrophy (ORPHA 1872)</td><td align="left">3.3. Senior-Loken syndrome (ORPHA 3156)</td><td align="left">5.3. Choroideremia (ORPHA 180)</td></tr><tr><td align="left">1.4. Late-onset retinal degeneration (ORPHA 67042)</td><td align="left">3.4. Joubert syndrome (ORPHA 475)</td><td align="left">5.4. Gyrate atrophy of choroid and retina (ORPHA 414)</td></tr><tr><td align="left">1.5. Leber congenital amaurosis (ORPHA 65)</td><td align="left">3.5. Usher syndrome (ORPHA 886)</td><td align="left">5.5. Helicoid peripapillary chorioretinal degeneration (ORPHA 86813)</td></tr><tr><td align="left"><p>1.6. Retinitis Pigmentosa AR</p><p>(ORPHA 791)</p></td><td align="left">3.6. Bardet-Biedl syndrome (ORPHA 110)</td><td align="left">5.6. Pigmented paravenous retinochoroidal atrophy (ORPHA 251295)</td></tr><tr><td align="left"><p>1.7. Retinitis Pigmentosa AD</p><p>(ORPHA 791)</p></td><td align="left">3.7. Hallervorden-Spatz syndrome (ORPHA 157850)</td><td align="left"><bold>6. HEREDITARY OPTIC NEUROPATHY (ORPHA 98671)</bold></td></tr><tr><td align="left"><p>1.8. Retinitis pigmentosa XL</p><p>(ORPHA 791)</p></td><td align="left">3.8. Syndromic retinitis pigmentosa—other (ORPHA 519325)</td><td align="left">6.1. Autosomal dominant optical atrophy (ORPHA 98672)</td></tr><tr><td align="left"><bold>1.9. Isolated macular dystrophy (ORPHA 519302)</bold></td><td align="left">3.9. Kearns-Sayre syndrome (ORPHA 480)</td><td align="left">6.2. Leber hereditary optic atrophy (ORPHA 104)</td></tr><tr><td align="left">1.9.1. Sorsby fundus dystrophy (59181)</td><td align="left">3.10. PXE (ORPHA 758)</td><td align="left">6.3. Hereditary optic neuropathy—other (98671)</td></tr><tr><td align="left">1.9.2. Stargardt disease (ORPHA 827)</td><td align="left">3.11. Alport Syndrome (ORPHA 63)</td><td align="left"/></tr><tr><td align="left">1.9.3. Best vitelliform macular dystrophy (ORPHA 1243)</td><td align="left">3.12. MIDD (ORPHA 225)</td><td align="left"><bold>7. OTHER RARE DISORDERS OF THE POSTERIOR SEGMENT OF THE EYE (ORPHA 519311)</bold></td></tr><tr><td align="left">1.9.4. North Carolina macular dystrophy (ORPHA 75327)</td><td align="left">3.13. Cuticular drusen/C3 Glomerulopathy (ORPHA 329918)</td><td align="left">7.1. Foveal hypoplasia (ORPHA 519398)</td></tr><tr><td align="left"><bold>1.10. Pattern dystrophy (ORPHA 63454)</bold></td><td align="left"><bold>4. INHERITED VITREOUS DYSTROPHIES (ORPHA 519304)</bold></td><td align="left">7.2. Coloboma (ORPHA 98942)</td></tr><tr><td align="left">1.10.1. Butterfly-shaped pigment dystrophy (ORPHA 99001)</td><td align="left">4.1. X-linked retinoschisis (ORPHA 792)</td><td align="left">7.3. Ocular albinism (ORPHA 284804)</td></tr><tr><td align="left">1.10.2. MFD simulating fundus flavimaculatus (ORPHA 99003)</td><td align="left">4.2. Stickler syndrome (ORPHA 828)</td><td align="left">7.4. Oculocutaneous albinism (ORPHA 55)</td></tr><tr><td align="left">1.10.3. Reticular dystrophy of the RPE (ORPHA 99002)</td><td align="left">4.3. Wagner disease (ORPHA 898)</td><td align="left">7.5. Other</td></tr><tr><td align="left">1.10.4. AOFVD (ORPHA 99000)</td><td align="left">4.4. FFEVR (OPRHA 891)</td><td align="left"/></tr><tr><td align="left"><bold>2. ISOLATED STATIONARY INHERITED RETINAL DISORDER (ORPHA 519319)</bold></td><td align="left">4.5. Goldmann-Favre syndrome/ESCS</td><td align="left"/></tr><tr><td align="left">2.1. Achromatopsia (ORPHA 49382)</td><td align="left">4.6. ADVIRC (ORPHA 3086)</td><td align="left"/></tr><tr><td align="left">2.2. CSNB (ORPHA 215)</td><td align="left"/><td align="left"/></tr><tr><td align="left">2.3. Fundus albipunctatus (ORPHA 227796)</td><td align="left"/><td align="left"/></tr><tr><td align="left">2.4. Familial drusen/Malattia leventinese (ORPHA 75376)</td><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>Bold corresponds to items (groups of diseases) that have dependences</p><p><italic>MFD</italic> multifocal pattern dystrophy, <italic>AOFVD</italic> adult-onset foveomacular vitelliform dystrophy, <italic>CSNB</italic> congenital stationary night blindness, <italic>PXE</italic> pseudoxanthoma elasticum, <italic>MIDD</italic> maternally-inherited diabetes and deafness, <italic>FEVR</italic> familial exudative vitreoretinopathy, <italic>ADVIRC</italic> autosomal-dominant vitreoretinochoroidopathy, <italic>CACD</italic> central areolar choroidal dystrophy</p><p><sup>a</sup>The platform allows the selection of more than one diagnosis</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>List of available IRD genes<sup>a</sup> and their respective Ontology of Genes and Genomes (OGG) and Mendelian Inheritance in Man (MIM) numbers</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">ABCA4</td><td align="left">OGG:3000000024</td><td align="left">MIM:601691</td><td align="left">LRAT</td><td align="left">OGG:3000009227</td><td align="left">MIM:604863</td></tr><tr><td align="left">ABCC6</td><td align="left">OGG:3000000368</td><td align="left">MIM:603234</td><td align="left">MAK</td><td align="left">OGG:3000004117</td><td align="left">MIM:154235</td></tr><tr><td align="left">ADGRV1</td><td align="left">OGG:3000084059</td><td align="left">MIM:602851</td><td align="left">MERTK</td><td align="left">OGG:3000010461</td><td align="left">MIM:604705</td></tr><tr><td align="left">AIPL1</td><td align="left">OGG:3000023746</td><td align="left">MIM:604392</td><td align="left">MT-ND1</td><td align="left">OGG:3000004535</td><td align="left">MIM:516000</td></tr><tr><td align="left">ALMS1</td><td align="left">OGG:3000007840</td><td align="left">MIM:606844</td><td align="left">MT-ND4</td><td align="left">OGG:3000004538</td><td align="left">MIM:516003</td></tr><tr><td align="left">BBS1</td><td align="left">OGG:3000000582</td><td align="left">MIM:209901</td><td align="left">MT-ND4L</td><td align="left">OGG:3000004539</td><td align="left">MIM:516004</td></tr><tr><td align="left">BBS10</td><td align="left">OGG:3000079738</td><td align="left">MIM:610148</td><td align="left">MT-ND6</td><td align="left">OGG:3000004541</td><td align="left">MIM:516006</td></tr><tr><td align="left">BBS12</td><td align="left">OGG:3000166379</td><td align="left">MIM:610683</td><td align="left">MT-TL1</td><td align="left">OGG:3000004567</td><td align="left">MIM:590050</td></tr><tr><td align="left">BBS2</td><td align="left">OGG:3000000583</td><td align="left">MIM:606151</td><td align="left">MYO7A</td><td align="left">OGG:3000004647</td><td align="left">MIM:276903</td></tr><tr><td align="left">BBS3/ARL6</td><td align="left">OGG:3000084100</td><td align="left">MIM:608845</td><td align="left">NMNAT1</td><td align="left">OGG:3000064802</td><td align="left">MIM:608700</td></tr><tr><td align="left">BBS4</td><td align="left">OGG:3000000585</td><td align="left">MIM:600374</td><td align="left">NR2E3</td><td align="left">OGG:3000010002</td><td align="left">MIM:604485</td></tr><tr><td align="left">BBS5</td><td align="left">OGG:3000129880</td><td align="left">MIM:603650</td><td align="left">NRL</td><td align="left">OGG:3000004901</td><td align="left">MIM:162080</td></tr><tr><td align="left">BBS7</td><td align="left">OGG:3000055212</td><td align="left">MIM:607590</td><td align="left">NYX</td><td align="left">OGG:3000060506</td><td align="left">MIM:300278</td></tr><tr><td align="left">BBS9</td><td align="left">OGG:3000027241</td><td align="left">MIM:607968</td><td align="left">OAT</td><td align="left">OGG:3000004942</td><td align="left">MIM:613349</td></tr><tr><td align="left">BEST1</td><td align="left">OGG:3000007439</td><td align="left">MIM:607854</td><td align="left">OPA1</td><td align="left">OGG:3000004976</td><td align="left">MIM:605290</td></tr><tr><td align="left">C1QTNF5</td><td align="left">OGG:3000114902</td><td align="left">MIM:608752</td><td align="left">OPN1LW</td><td align="left">OGG:3000005956</td><td align="left">MIM:300822</td></tr><tr><td align="left">CACNA1F</td><td align="left">OGG:3000000778</td><td align="left">MIM:300110</td><td align="left">PANK2</td><td align="left">OGG:3000080025</td><td align="left">MIM:606157</td></tr><tr><td align="left">CDH23</td><td align="left">OGG:3000064072</td><td align="left">MIM:605516</td><td align="left">PAX6</td><td align="left">OGG:3000005080</td><td align="left">MIM:607108</td></tr><tr><td align="left">CEP290</td><td align="left">OGG:3000080184</td><td align="left">MIM:610142</td><td align="left">PCARE</td><td align="left">OGG:3000388939</td><td align="left">MIM:613425</td></tr><tr><td align="left">CERKL</td><td align="left">OGG:3000001399</td><td align="left">MIM:608381</td><td align="left">PDE6A</td><td align="left">OGG:3000005145</td><td align="left">MIM:180071</td></tr><tr><td align="left">CFH</td><td align="left">OGG:3000003075</td><td align="left">MIM:134370</td><td align="left">PDE6B</td><td align="left">OGG:3000005158</td><td align="left">MIM:180072</td></tr><tr><td align="left">CHM</td><td align="left">OGG:3000001121</td><td align="left">MIM:300390</td><td align="left">PDE6C</td><td align="left">OGG:3000005146</td><td align="left">MIM:600827</td></tr><tr><td align="left">CLN3</td><td align="left">OGG:3000001201</td><td align="left">MIM:607042</td><td align="left">PDE6G</td><td align="left">OGG:3000005148</td><td align="left">MIM:180073</td></tr><tr><td align="left">CLRN1</td><td align="left">OGG:3000007401</td><td align="left">MIM:606397</td><td align="left">PHYH</td><td align="left">OGG:3000005264</td><td align="left">MIM:602026</td></tr><tr><td align="left">CNGA3</td><td align="left">OGG:3000001261</td><td align="left">MIM:600053</td><td align="left">POC1B</td><td align="left">OGG:3000282809</td><td align="left">MIM:614784</td></tr><tr><td align="left">CNGB1</td><td align="left">OGG:3000001258</td><td align="left">MIM:600724</td><td align="left">PRCD</td><td align="left">OGG:3000768206</td><td align="left">MIM:610598</td></tr><tr><td align="left">CNGB3</td><td align="left">OGG:3000054714</td><td align="left">MIM:605080</td><td align="left">PROM1</td><td align="left">OGG:3000008842</td><td align="left">MIM:604365</td></tr><tr><td align="left">CNNM4</td><td align="left">OGG:3000026504</td><td align="left">MIM:607805</td><td align="left">PRPF3</td><td align="left">OGG:3000009129</td><td align="left">MIM:607301</td></tr><tr><td align="left">COL2A1</td><td align="left">OGG:3000001280</td><td align="left">MIM:120140</td><td align="left">PRPF31</td><td align="left">OGG:3000026121</td><td align="left">MIM:606419</td></tr><tr><td align="left">COL4A3</td><td align="left">OGG:3000001285</td><td align="left">MIM:120070</td><td align="left">PRPF8</td><td align="left">OGG:3000010594</td><td align="left">MIM:607300</td></tr><tr><td align="left">COL4A4</td><td align="left">OGG:3000001286</td><td align="left">MIM:120131</td><td align="left">PRPH2 (RDS)</td><td align="left">OGG:3000005961</td><td align="left">MIM:179605</td></tr><tr><td align="left">COL4A5</td><td align="left">OGG:3000001287</td><td align="left">MIM:303630</td><td align="left">RDH12</td><td align="left">OGG:3000145226</td><td align="left">MIM:608830</td></tr><tr><td align="left">CRB1</td><td align="left">OGG:3000023418</td><td align="left">MIM:604210</td><td align="left">RDH5</td><td align="left">OGG:3000005959</td><td align="left">MIM:601617</td></tr><tr><td align="left">CRX</td><td align="left">OGG:3000001406</td><td align="left">MIM:602225</td><td align="left">RHO</td><td align="left">OGG:3000006010</td><td align="left">MIM:180380</td></tr><tr><td align="left">CYP4V2</td><td align="left">OGG:3000285440</td><td align="left">MIM:608614</td><td align="left">RIMS1</td><td align="left">OGG:3000022999</td><td align="left">MIM:606629</td></tr><tr><td align="left">DHDDS</td><td align="left">OGG:3000079947</td><td align="left">MIM:608172</td><td align="left">RLBP1</td><td align="left">OGG:3000006017</td><td align="left">MIM:180090</td></tr><tr><td align="left">EFEMP1</td><td align="left">OGG:3000002202</td><td align="left">MIM:601548</td><td align="left">RP1</td><td align="left">OGG:3000006101</td><td align="left">MIM:3937</td></tr><tr><td align="left">ELOVL4</td><td align="left">OGG:3000006785</td><td align="left">MIM:605512</td><td align="left">RP2</td><td align="left">OGG:3000006102</td><td align="left">MIM:300757</td></tr><tr><td align="left">EYS</td><td align="left">OGG:3000346007</td><td align="left">MIM:612424</td><td align="left">RPE65</td><td align="left">OGG:3000006121</td><td align="left">MIM:180069</td></tr><tr><td align="left">FAM161A</td><td align="left">OGG:3000084140</td><td align="left">MIM:613596</td><td align="left">RPGR</td><td align="left">OGG:3000006103</td><td align="left">MIM:312610</td></tr><tr><td align="left">GNAT1</td><td align="left">OGG:3000002779</td><td align="left">MIM:139330</td><td align="left">RPGRIP1</td><td align="left">OGG:3000057096</td><td align="left">MIM:605446</td></tr><tr><td align="left">GNAT2</td><td align="left">OGG:3000002780</td><td align="left">MIM:139340</td><td align="left">RS1</td><td align="left">OGG:3000006247</td><td align="left">MIM:300839</td></tr><tr><td align="left">GPR98</td><td align="left">OGG:3000084059</td><td align="left">MIM:602851</td><td align="left">SAG</td><td align="left">OGG:3000006295</td><td align="left">MIM:181031</td></tr><tr><td align="left">GRK1</td><td align="left">OGG:3000006011</td><td align="left">MIM:180381</td><td align="left">SEMA4A</td><td align="left">OGG:3000064218</td><td align="left">MIM:607292</td></tr><tr><td align="left">GUCA1A</td><td align="left">OGG:3000002978</td><td align="left">MIM:600364</td><td align="left">SNRNP200</td><td align="left">OGG:3000023020</td><td align="left">MIM:601664</td></tr><tr><td align="left">GUCA1B</td><td align="left">OGG:3000002979</td><td align="left">MIM:602275</td><td align="left">SPATA7</td><td align="left">OGG:3000055812</td><td align="left">MIM:609868</td></tr><tr><td align="left">GUCY2D</td><td align="left">OGG:3000003000</td><td align="left">MIM:600179</td><td align="left">TIMP3</td><td align="left">OGG:3000007078</td><td align="left">MIM:188826</td></tr><tr><td align="left">HGSNAT</td><td align="left">OGG:3000138050</td><td align="left">MIM:610453</td><td align="left">TOPORS</td><td align="left">OGG:3000010210</td><td align="left">MIM:609507</td></tr><tr><td align="left">IMPDH1 (RP10)</td><td align="left">OGG:3000003614</td><td align="left">MIM:146690</td><td align="left">TULP1</td><td align="left">OGG:3000007287</td><td align="left">MIM:602280</td></tr><tr><td align="left">IMPG1</td><td align="left">OGG:3000003617</td><td align="left">MIM:602870</td><td align="left">USH1G</td><td align="left">OGG:3000124590</td><td align="left">MIM:607696</td></tr><tr><td align="left">IMPG2</td><td align="left">OGG:3000050939</td><td align="left">MIM:607056</td><td align="left">USH2A</td><td align="left">OGG:3000007399</td><td align="left">MIM:608400</td></tr><tr><td align="left">IQCB1</td><td align="left">OGG:3000009657</td><td align="left">MIM:609237</td><td align="left">VCAN</td><td align="left">OGG:3000001462</td><td align="left">MIM:118661</td></tr><tr><td align="left">KCNV2</td><td align="left">OGG:3000169522</td><td align="left">MIM:607604</td><td align="left">WDR19</td><td align="left">OGG:3000057728</td><td align="left">MIM:608151</td></tr><tr><td align="left">KLHL7</td><td align="left">OGG:3000055975</td><td align="left">MIM:11119</td><td align="left">Other</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">LCA5</td><td align="left">OGG:3000167691</td><td align="left">MIM:611408</td><td align="left">Inconclusive</td><td align="left">N/A</td><td align="left">N/A</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The user may select one, two or more genes in case clinically relevant variants are found in more than one gene. This list may be edited with newer additions in case other genes are found in the Portuguese population with IRDs</p></table-wrap-foot></table-wrap></p>
      <p id="Par9">We were able to design an interoperable module by reusing the <italic>retina.pt</italic> core data elements where appropriate (epidemiological data such as sex, date of birth and patient ID), whilst also incorporating bespoke data elements, sections and forms for the specific field of IRDs (Table <xref rid="Tab3" ref-type="table">3</xref>). Upon selection of a particular item (clinical diagnosis, signs and symptoms, syndromic features, gene or additional diagnoses), a hyperlink is available to direct the user to the correspondent ontology webpage (ORPHA, HPO, OGG).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Data set for the IRD-PT module, including the Human Phenotype Oncology (HPO) coding when applicable</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Field</th><th align="left">Type of entry</th><th align="left">Answer</th><th align="left">Available options</th></tr></thead><tbody><tr><td align="left">1. Patient ID</td><td align="left">Free text</td><td align="left">Mandatory</td><td align="left"/></tr><tr><td align="left">2. Date of birth</td><td align="left">Date format</td><td align="left">Mandatory</td><td align="left"/></tr><tr><td align="left">3. Sex</td><td align="left">Select from list</td><td align="left">Mandatory</td><td align="left">Male; female</td></tr><tr><td align="left">4. Date of diagnosis</td><td align="left">Date format</td><td align="left">Mandatory</td><td align="left"/></tr><tr><td align="left">5. Clinical diagnosis</td><td align="left">Select from list (allows selection of more than one option)</td><td align="left">Mandatory</td><td align="left">See Table <xref rid="Tab1" ref-type="table">1</xref></td></tr><tr><td align="left">6. Consanguinity</td><td align="left">Select from list</td><td align="left">Mandatory</td><td align="left">Yes; no; suspected</td></tr><tr><td align="left">7. Family history</td><td align="left">Select from list</td><td align="left">Mandatory</td><td align="left">Yes; no; suspected</td></tr><tr><td align="left"> 7.1. Family linkage section (only shows if the user answered Yes to the previous question)</td><td align="left" colspan="3">Allows introduction of one or multiple affected family members, including their family relation to the patient (brother; sister; mother; father; son; daughter; uncle; aunt; cousin; grandfather; grandmother; other) and Hospital ID which has a hyperlink to that patient’s page in case he/she has consented to be part of the registry</td></tr><tr><td align="left">8. Signs and symptoms</td><td align="left">Select from list (allows selection of more than one option)</td><td align="left">Mandatory</td><td align="left">Nyctalopia (HP:0000662); decreased VA (HP:0000529); photophobia (HP:0000613); color vision defects (HP:0000551); central scotoma (HP:0000603); constricted visual field (HP:0001133); photopsia (HP:0030786); nystagmus (HP:0,000,639); headache (HP:0002315); migraine (HP:0002076); visual hallucinations (HP:0002367); other</td></tr><tr><td align="left">9. Age of onset of symptoms</td><td align="left">Select from list</td><td align="left">Mandatory</td><td align="left">at birth; &lt; 5; 6–10; 11–20; 21–30; 31–50; &gt; 51</td></tr><tr><td align="left">10. Syndromic features</td><td align="left">Select from list</td><td align="left">Mandatory</td><td align="left">Yes/no</td></tr><tr><td align="left"> 10.1. Syndromic features list (only shows if the user answered yes to the previous question)</td><td align="left">Select from list (allows selection of more than one option)</td><td align="left">Optional</td><td align="left">Hearing loss/deafness (HP:0008527); obesity (HP:0001513); hypogonadism (HP:0000135); diabetes mellitus (HP:0000819); diabetes insipidus (HP:0000873); polydactyly (HP:0010442); other skeletal abnormalities (HP:0000924); cognitive impairment (HP:0100543); developmental delay (HP:0001263); seizures (HP:0001250); ataxia (HP:0001251); dysarthria (HP:0001260); renal insufficiency (HP:0000083); other</td></tr><tr><td align="left">11. Genetic testing</td><td align="left">Select from list</td><td align="left">Mandatory</td><td align="left">Yes/no</td></tr><tr><td align="left"> 11.1. Type of test (only shows if the user answered yes to genetic testing)</td><td align="left">Select from list (allows selection of more than one option)</td><td align="left">Optional</td><td align="left">Sanger sequencing; NGS panel; WES; MLPA; don’t know; other</td></tr><tr><td align="left"> 11.2. Gene (only shows if the user answered yes to genetic testing)</td><td align="left">Select from list (allows selection of more than one option)</td><td align="left">Optional</td><td align="left">See Table <xref rid="Tab2" ref-type="table">2</xref></td></tr><tr><td align="left"> 11.3. Variants<sup>a</sup> (only shows if the user answered yes to genetic testing)</td><td align="left">Free text</td><td align="left">Optional</td><td align="left"/></tr><tr><td align="left"> 11.4. Classification of variants (ACMG) (only shows if the user answered yes to genetic testing)</td><td align="left">Select from list (for each introduced variant)</td><td align="left">Optional</td><td align="left">Pathogenic; likely pathogenic; VUS</td></tr><tr><td align="left">BCVA<sup>b</sup></td><td align="left">Select from list</td><td align="left">Mandatory</td><td align="left">From 20/1000 to 20/10</td></tr><tr><td align="left">IOP<sup>b</sup></td><td align="left">Free text</td><td align="left">Optional</td><td align="left">Only accepts numbers from 01 to 99</td></tr><tr><td align="left">Additional diagnoses<sup>b</sup></td><td align="left">Select from list (allows selection of more than one option)</td><td align="left">Optional</td><td align="left">Amblyopia (HP:0000646); cataract (HP:0000518); CNV (HP:0011506); CME (HP:0011505); glaucoma (HP:0000501); ERM (HP:0100014); macular hole (HP:0011508); lamellar hole (HP:0001103); macular pseudohole (HP:0001103); vitreomacular traction (HP:0031151); retinal detachment (HP:0000541); keratoconus (HP:0000563); strabismus (HP:0000486); other</td></tr><tr><td align="left">Previous treatments<sup>b</sup></td><td align="left">Select from list (allows selection of more than one option)</td><td align="left">Optional</td><td align="left">Vitreoretinal surgery; strabismus surgery; glaucoma surgery; YAG laser capsulotomy; corneal transplant; cataract surgery; intravitreal injection; subretinal injection; laser photocoagulation; refractive surgery; other</td></tr></tbody></table><table-wrap-foot><p><italic>DOB</italic> date of birth, <italic>NGS</italic> next generation sequencing, <italic>WES</italic> whole exome sequencing, <italic>MLPA</italic> multiplex ligation-dependent probe amplification, <italic>ACMG</italic> American College of Medical Genetics and Genomics, <italic>VUS</italic> variant of uncertain significance, <italic>BCVA</italic> best corrected visual acuity, <italic>IOP</italic> intraocular pressure, <italic>CNV</italic> choroidal neovascularization, <italic>CME</italic> cystoid macular edema, <italic>ERM</italic> epiretinal membrane</p><p><sup>a</sup>Apart from listing the variants as free text, an icon is available for the upload of the raw sequencing file</p><p><sup>b</sup>These fields appear separately for the right and left eye</p></table-wrap-foot></table-wrap></p>
      <p id="Par10">The family linkage section allows simple viewing of the details of affected family members that are also part of the registry. At the end of each visit, a free text area is available for comments (follow-up, imaging, prescription, etc.).</p>
      <p id="Par11">Longitudinal data is captured through specific follow-up forms. The platform allows retrospective data introduction. As the program develops, and through alignment with international data collection for IRD clinical registries, the IRD-PT core data set may be modified or extended to include additional key clinical variables.</p>
    </sec>
    <sec id="Sec4">
      <title>Data analysis and graphical displays</title>
      <p id="Par12">Since the <italic>retina.pt</italic> was designed to be both a registry and a research tool, data export and analysis features are very important. A search engine that allows data filtering is available for the user to search specific anonymized data, such as the total number of affected patients or the total number of affected families with a certain disease-causing gene, clinical diagnosis, BCVA level, etc. Furthermore, the platform offers statistical tools for simple analyses and these are also available for the IRD-PT module (Figs. <xref rid="Fig1" ref-type="fig">1</xref>, <xref rid="Fig2" ref-type="fig">2</xref>). For more sophisticated analyses, users can export their own data on <italic>excel</italic> format and analyze it as they see fit. Data are aggregated in an anonymized fashion, without identification of the individual patients.<fig id="Fig1"><label>Fig. 1</label><caption><p>Variation in the percentage of eyes with different levels of BCVA (ETDRS letters) over time (last-observation carried forward) in the 45 patients (90 eyes) with Usher syndrome included in the IRD-PT registry so far. The graph is automatically provided by the platform. The user may select which parameters to show. It is also possible to select only one eye per patient</p></caption><graphic xlink:href="13023_2020_1591_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Progression of BCVA (ETDRS letters) over follow-up (last-observation carried forward) in eyes with any IRD that started with driving vision (≥ 70 ETDRS letters). Each green line corresponds to an eye of an individual patient. The graph is automatically provided by the platform. The user may select which parameters to show</p></caption><graphic xlink:href="13023_2020_1591_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec5">
      <title>Participant characteristics</title>
      <p id="Par13">So far, the <italic>retina.pt</italic> platform has been approved by the Human Research Ethics Committee (HREC)/Institutional Review Board (IRB) of 52 health care providers across Portugal. Each of these hospitals/clinics has established the necessary infrastructure to support rapid rollout of site and patient recruitment, data collection, and data transfer. One-hundred and thirty five users (doctors/investigators) have applied for credentials to access the registry, and 58 of these have already included patient data. To date, there are over 1800 participants (patients) and over 30,000 consultations included in the registry. In mid 2019, the IRD-PT module was pre-launched at <italic>Centro Hospitalar e Universitário de Coimbra</italic> (CHUC), the only Portuguese health care provider (HCP) that is a member of the ERN-EYE, and the largest reference center for IRDs in Portugal. The idea of testing the registry in one dedicated center before its national debut was aimed to identify possible problems during data completion, test the time spent in data entry, and detect information gaps or system inaccuracies. The registry proved fully functional, fast and easy to use. As of April 1st 2020, finalized data from 537 participants were available for this preliminary analysis. Considering the Portuguese population (~ 10 million inhabitants), this number corresponds to roughly 1/6 of the total estimated cases of IRDs in Portugal. The distribution of the clinical diagnoses and their relative frequency among the included participants is shown in Table <xref rid="Tab4" ref-type="table">4</xref>. As illustrated in Fig. <xref rid="Fig3" ref-type="fig">3</xref>, syndromic (14%) and non-syndromic retinitis pigmentosa (36%) account for 50% of the clinical diagnoses. The percentage of genetically solved and unsolved cases of syndromic and non-syndromic RP is shown in Fig. <xref rid="Fig4" ref-type="fig">4</xref>. Of all participants included in the IRD-PT registry to date, 57% are women and the mean age at the index visit was 39.27 ± 19.03 years. Average baseline BCVA was 54.36 ± 27.22 and final BCVA was 47.64 ± 28.92 ETDRS letters.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Distribution of the clinical IRD diagnoses and their relative frequency among the 537 subjects included in the IRD-PT registry</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinical diagnosis</th><th align="left">n</th><th align="left">Relative frequency (%)</th></tr></thead><tbody><tr><td align="left">Non-syndromic RP</td><td align="left">192</td><td char="." align="char">35.75</td></tr><tr><td align="left">Syndromic RP</td><td align="left">74</td><td char="." align="char">13.78</td></tr><tr><td align="left">Cone/cone-rod dystrophy</td><td align="left">62</td><td char="." align="char">11.55</td></tr><tr><td align="left">Stargardt disease</td><td align="left">27</td><td char="." align="char">5.03</td></tr><tr><td align="left">PXE</td><td align="left">21</td><td char="." align="char">3.91</td></tr><tr><td align="left">Pattern dystrophy</td><td align="left">20</td><td char="." align="char">3.72</td></tr><tr><td align="left">ADOA (Kjer)</td><td align="left">14</td><td char="." align="char">2.61</td></tr><tr><td align="left">Leber congenital amaurosis</td><td align="left">12</td><td char="." align="char">2.23</td></tr><tr><td align="left">Best vitelliform macular dystrophy</td><td align="left">12</td><td char="." align="char">2.23</td></tr><tr><td align="left">Foveal hypoplasia</td><td align="left">11</td><td char="." align="char">2.05</td></tr><tr><td align="left">X-linked retinoschisis</td><td align="left">10</td><td char="." align="char">1.86</td></tr><tr><td align="left">PPRCA</td><td align="left">7</td><td char="." align="char">1.30</td></tr><tr><td align="left">Achromatopsia</td><td align="left">6</td><td char="." align="char">1.12</td></tr><tr><td align="left">Ocular/oculocutaneous albinism</td><td align="left">6</td><td char="." align="char">1.12</td></tr><tr><td align="left">CACD</td><td align="left">6</td><td char="." align="char">1.12</td></tr><tr><td align="left">Choroideremia</td><td align="left">6</td><td char="." align="char">1.12</td></tr><tr><td align="left">CSNB</td><td align="left">5</td><td char="." align="char">0.93</td></tr><tr><td align="left">Coloboma</td><td align="left">5</td><td char="." align="char">0.93</td></tr><tr><td align="left">ARB</td><td align="left">4</td><td char="." align="char">0.74</td></tr><tr><td align="left">Bietti crystalline dystrophy</td><td align="left">4</td><td char="." align="char">0.74</td></tr><tr><td align="left">Fundus albipunctatus</td><td align="left">4</td><td char="." align="char">0.74</td></tr><tr><td align="left">MIDD</td><td align="left">4</td><td char="." align="char">0.74</td></tr><tr><td align="left">Gyrate atrophy of choroid and retina</td><td align="left">3</td><td char="." align="char">0.56</td></tr><tr><td align="left">Goldmann-Favre syndrome/ESCS</td><td align="left">3</td><td char="." align="char">0.56</td></tr><tr><td align="left">Stickler/Wagner syndrome</td><td align="left">3</td><td char="." align="char">0.56</td></tr><tr><td align="left">Cuticular drusen/C3 glomerulopathy</td><td align="left">3</td><td char="." align="char">0.56</td></tr><tr><td align="left">LORD</td><td align="left">3</td><td char="." align="char">0.56</td></tr><tr><td align="left">LHON</td><td align="left">3</td><td char="." align="char">0.56</td></tr><tr><td align="left">ADVIRC</td><td align="left">2</td><td char="." align="char">0.37</td></tr><tr><td align="left">Retinitis punctata albescens</td><td align="left">2</td><td char="." align="char">0.37</td></tr><tr><td align="left">Alport syndrome</td><td align="left">2</td><td char="." align="char">0.37</td></tr><tr><td align="left">NCMD</td><td align="left">1</td><td char="." align="char">0.19</td></tr></tbody></table><table-wrap-foot><p><italic>RP</italic> retinitis pigmentosa, <italic>PXE</italic> pseudoxanthoma elasticum, <italic>ADOA</italic> autosomal dominant optic atrophy, <italic>PPRCA</italic> pigmented paravenous retinochoroidal atrophy, <italic>CACD</italic> central areolar choroidal dystrophy, <italic>CSNB</italic> congenital stationary night blindness, <italic>ARB</italic> autosomal recessive bestrophinopathy, <italic>MIDD</italic> maternally inherited diabetes and deafness, <italic>ESCS</italic> enhanced S-cone syndrome, <italic>LORD</italic> late-onset retinal degeneration, <italic>LHON</italic> leber hereditary optic neuropathy, <italic>ADVIRC</italic> autosomal dominant vitreoretinochoroidopathy, <italic>NCMD</italic> North Carolina macular dystrophy</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Graphical representation of the relative frequency of each clinical diagnosis in the 537 patients included in the IRD-PT registry. Those with &lt; 1% cases are expressed under the tag <italic>Other</italic>. <italic>RP</italic> retinitis pigmentosa, <italic>PXE</italic> pseudoxanthoma elasticum, <italic>ADOA</italic> autosomal dominant optic atrophy, <italic>PPRCA</italic> pigmented paravenous retinochoroidal atrophy, <italic>CACD</italic> central areolar choroidal dystrophy</p></caption><graphic xlink:href="13023_2020_1591_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Graphical representation of the percentage of genetically solved and genetically unsolved cases of syndromic and non-syndromic retinitis pigmentosa in our cohort</p></caption><graphic xlink:href="13023_2020_1591_Fig4_HTML" id="MO4"/></fig></p>
    </sec>
  </sec>
  <sec id="Sec6">
    <title>Discussion</title>
    <p id="Par14">Appropriate design, implementation and deployment of patient registries enables rapid decision making and ongoing data mining, ultimately leading to improved patient outcomes [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In the specific field of rare diseases, the use of registries increases research accessibility for individuals, while providing clinicians/investigators with a coherent data ecosystem necessary to boost research. The IRD-PT module of <italic>retina.pt</italic> will facilitate the efficient capture of accurate, longitudinal, country-wide data for IRDs. The registry will provide valuable information on disease prevalence, genomic landscape, genotype–phenotype correlations and natural history of IRDs, which is currently an unmet need in Portugal. Furthermore, the registry will facilitate patient selection for newly approved treatments or enrollment in clinical trials. The use of a web-based data storage system allows the registry to extend recruitment across multiple centers in the country. The modular design and scalable nature of the framework used to deploy the IRD-PT registry make it easily adaptable over time, ensuring its long-term sustainability. Furthermore, the use of domain-specific ontologies adds value to data, through an integrated knowledge base that is searchable and comparable by user and by machines [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In fact, by resorting to common data elements, core outcome sets, and standardized data structures, the IRD-PT module can support the exchange of data across datasets, facilitating the connection to other registries at an international level. The interoperability of this registry by means of data harmonization is a key feature pointing to its utility and scalability. Another important issue of a web-based registry is usability, i.e. the capacity of a software system to provide conditions for its users to perform the tasks satisfactorily, effectively, and efficiently. Ophthalmologists have limited time with patients during office visits, and electronic health record (EHR) use requires a substantial portion of that time, therefore affecting productivity [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The <italic>retina.pt</italic> registry combines a user-friendly platform and reduced load of data entry with the possibility to generate a <italic>pdf</italic> document that can be saved, printed or copied to the hospital EHR system, thus eliminating the need for duplicate records. Additionally, there is also the possibility of EHR third party applications with structured information to deliver their data directly to specific subfields of the registry, thus enabling a quick fill in process. The detailed information provided on Table <xref rid="Tab3" ref-type="table">3</xref> regarding data capture for the IRD-PT may be used to modify EHR systems to allow for direct data transfer. Finally, the versatility of the platform, makes it possible to serve as electronic case report form (eCRF) for upcoming observational, natural-history or post-market authorization studies.</p>
    <p id="Par15">The IRD-PT is not exempt of limitations. An important principle in registry design is to reduce the load of data entry. This does not come without a price. By limiting the data that is considered mandatory to a minimum, there may be incomplete information/missing data for some included subjects concerning unanswered non-mandatory fields. Another limitation is that grading systems/levels for the symptoms or degree of impairment are not available. The fact that symptoms are simply marked as present/not present prevents a precise characterization of these symptoms during the disease course. Finally, since each user is responsible for its own data entry, we cannot be sure about the accuracy of its contents. This may be particularly problematic when a case is considered molecularly solved or unsolved. Misinterpretation of the genetic findings is not uncommon, which may lead to selection bias regarding the number of molecularly solved/unsolved cases.</p>
  </sec>
  <sec id="Sec7">
    <title>Conclusions</title>
    <p id="Par16">We have described here the principles behind the design, development and deployment of a web-based software tool that forms the basis of a nation-wide registry for IRDs. The pre-launch of the IRD-PT module in the largest Portuguese referral center for IRDs (CHUC), allowed to test the functionalities of the registry and enroll the first 537 IRD patients, roughly 1/6 of the total estimated cases of IRDs in Portugal. Now that the module is fully working, recruitment will be extended to other Portuguese hospitals. Judging from the enthusiasm and adherence observed with the launch of the <italic>retina.pt</italic> platform, we believe that the IRD-PT registry will be rapidly adopted by the Portuguese ophthalmologists managing IRD patients. Our hope is to generate important knowledge and collect high-quality data on the epidemiology, genomic landscape, genotype–phenotype correlations and natural history of IRDs in Portugal. This will both boost and excel clinical research in the field of IRDs in our country, while facilitating patient access to clinical trials or new therapies.</p>
  </sec>
  <sec id="Sec8">
    <title>Methods</title>
    <sec id="Sec9">
      <title>Registry design</title>
      <p id="Par17">The IRD-PT is a clinical/genetic research registry. Its main goal is to create a national, web-based registry of IRDs in Portugal that allows to study their prevalence, genomic profile, genotype–phenotype correlations and natural history. Also, the registry may assist in the recruitment of participants for new treatments/clinical trials, and provide support for the establishment of disease-specific standards and care. The IRD-PT registry is included in the <italic>retina.pt</italic> platform (<ext-link ext-link-type="uri" xlink:href="https://www.retina.com.pt">https://www.retina.com.pt</ext-link>), which was developed by the Portuguese Retina Study Group (GER, <ext-link ext-link-type="uri" xlink:href="http://www.ger-portugal.com">www.ger-portugal.com</ext-link>). The <italic>retina.pt</italic> registry deployed in 2017 to fulfil a vital component on patient-centered care for retinal diseases. It collects data on individuals diagnosed with retinal diseases, from several sites across Portugal, with over 1800 participants and over 30,000 consultations to date. The IRD-PT is a module interacting with the <italic>retina.pt</italic> core system. The core system provides a range of basic functions used for patient data management, while the IRD-PT module provides the user with the functionality to capture data for the specific purpose of IRDs.</p>
    </sec>
    <sec id="Sec10">
      <title>Recruitment and informed consent</title>
      <p id="Par18">Both pediatric and adult patients with a genetic and/or clinical diagnosis of IRD living in Portugal and attending Ophthalmology clinics around the country are invited to participate. Participation in the registry is voluntary. Before enrollment, the participant (patient) or their legally authorized representative must provide informed consent for the collection, storage, and use of their personal health data. No costs or compensations are involved for participants or their family members as the data collected in the IRD-PT module refers to information routinely collected by the responsible physician. All included subjects are allowed to withdraw their consent at any time, without providing a reason. This does not impact their regular follow-up at the clinic.</p>
    </sec>
    <sec id="Sec11">
      <title>Ethics and regulations</title>
      <p id="Par19">The registry meets the necessary requirements for compliance with the General Data Protection Regulation (GDPR) of the European Union and all approvals were obtained prior to recruiting patients for the registry. Formal review and approval was obtained from the Portuguese Data Protection Authority (<italic>Comissão Nacional de Proteção de Dados</italic>—CNPD), HREC of <italic>Centro Hospitalar e Universitário de Coimbra</italic> (CHUC) and IRB of the Faculty of Medicine of the University of Coimbra (FMUC). All these independent entities ensured that the study protocol, governance, protections, and methods were ethical and appropriate. Furthermore, each participating core center needs to obtain approval from the respective Ethics Committee. Documentation of approval from each center is copied to the central governing office to ensure currency of approval is maintained.</p>
      <p id="Par20">All investigators (users) are mandated to sign the Investigator Declaration Form before obtaining credentials to use the registry. Both the project investigators and their institutions permit project-related monitoring, audits, and regulatory inspections, providing direct access to source data/documents. This may include, but is not limited to, review by HREC and institutional governance review bodies.</p>
    </sec>
    <sec id="Sec12">
      <title>Data protection</title>
      <p id="Par21">Proper handling of ethical, legal, social, and privacy issues must be a foundational component of the design, implementation, and long-term sustainability of a patient registry [<xref ref-type="bibr" rid="CR7">7</xref>]. As part of the <italic>retina.pt</italic>, the IRD-PT module was designed to provide maximum data security and patient anonymity. Several well-defined procedures were put in place to protect individual patient data within the registry study. Data security, integrity, and availability is monitored and regulated.</p>
      <p id="Par22">All data transmissions between the user and the server are encrypted using 128-bit encryption (Secure Sockets Layer). The data are stored and backed up on secure servers at Portugal Telecom—Altice, TEAR 3 certified Datacenter. Anonymity of users is also closely guarded. Individual users can only see their own data. However, users may find other centers with included data on a specific disease and ask for research collaborations within the platform. Users can withdraw their data from the registry at any time, without providing a reason.</p>
    </sec>
    <sec id="Sec13">
      <title>Registry interface</title>
      <p id="Par23">Drop-down menus, pop-up explanatory notes, and tab-to-jump ensures rapid and user friendly data entry. Furthermore, <italic>retina.pt</italic> is a web-based application that is able to run on different server operating systems. Any device with Internet access and a recent browser can be used to interact with the application. Additional software on the user’s terminal is not required. When all mandatory fields have been filled, the User can “Finalize” the visit by pressing “Save”. The system has been designed in such a way that it will not allow a visit to be finalized unless all the mandatory fields have been filled and all numerical data fall within prespecified ranges. Additionally, the platform allows data to be automatically filled in by third party EHR applications with identically structured information, or the possibility of the user to generate a <italic>pdf</italic> document that can be printed/copied to the hospital EHR system. Moreover, storage and retrieval of clinical images is possible in the patient-specific page.</p>
    </sec>
    <sec id="Sec14">
      <title>Data quality</title>
      <p id="Par24">High quality data of rare diseases registries is considered to be one of the most important elements in the establishment and maintenance of a registry [<xref ref-type="bibr" rid="CR20">20</xref>]. Quality assurance includes quality improvement activities such as medical, clinical, and record audit and observational studies, to which the ethical principles of research apply.</p>
    </sec>
    <sec id="Sec15">
      <title>Interoperability</title>
      <p id="Par25">Upon the development of the <italic>retina.pt</italic> platform, interoperability was a key issue. First, the registry has two available languages to choose from: Portuguese and English. Second, the age-related macular degeneration (AMD) module of <italic>retina.pt</italic> is already linked to the Fight Retinal Blindness! (FRB!) Project registry [<xref ref-type="bibr" rid="CR2">2</xref>] and efforts are in place to connect it to the International Consortium for Health Outcomes Measurement (ICHOM) AMD registry. Third, the platform is serving as the eCRF for an upcoming post-market authorization clinical trial. Rare diseases are a prime example of a research area that can strongly profit from coordination on a European and international scale. To allow interoperability of the IRD-PT module with other IRD registries across the world, all the diseases are coded accordingly to ICD9, ICD10, ICD11, and ORDO (ORPHA codes) numbers. Furthermore, the genes are coded according to the OGG and MIM, and patient signs and symptoms are coded according to HPO. This is in accordance with the eye-specific dataset of the Clinical Patient Management System (CPMS) of the ERN-EYE [<xref ref-type="bibr" rid="CR17">17</xref>]. Notably, ORDO, HPO, OGG and MIM are open-access, interoperable, community-driven, available in multiple languages and regularly updated.
</p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>The authors would like to acknowledge Sara Costa, Paulo Castro and Carlos Castro, members of Inovasis, for the critical IT support during the development and deployment of the <italic>retina.pt</italic> platform in general and the IRD-PT module in particular. The authors would also like to acknowledge Novartis Portugal and the Portuguese Society of Ophthalmology for the funding that made the development of the IRD-PT module possible.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors’ contributions</title>
    <p>JPM conceptualized, designed and drafted the manuscript. JH and RS conceptualized and substantively revised the manuscript. ALC, JS and JNM substantively revised the manuscript. All authors have read and approved the submitted version, and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>The <italic>retina.pt</italic> platform receives annual funding from industry stakeholders (Novartis, Bayer, Allergan and Alimera). This is used for data management activities, IT support, layout improvements and legal support. None of the aforementioned companies had any interference on the design or development of the registry, nor have any type of proprietary interest in the generated data. The IRD-PT module received specific funding for its development and implementation, namely for IT support, data management activities, design and layout. This came as a grant from Novartis Portugal and the Portuguese Society of Ophthalmology. Neither entity had, has or will have any interference on the collection, analysis, and/or interpretation of data, nor have any type of proprietary interest in the generated data.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
  </notes>
  <notes id="FPar1">
    <title>Ethics approval and consent to participate</title>
    <p id="Par26">Formal review and approval was obtained from the Portuguese Data Protection Authority (<italic>Comissão Nacional de Proteção de Dados—</italic>CNPD), Human Research Ethics Committee (HREC) of <italic>Centro Hospitalar e Universitário de Coimbra</italic> (CHUC) and Institutional Review Board (IRB) of the Faculty of Medicine of the University of Coimbra (FMUC). Additionally, each participating core health care provider needs to obtain approval from the respective Ethics Committee. Documentation of approval from each center is copied to the central governing office to ensure currency of approval is maintained.</p>
  </notes>
  <notes id="FPar2">
    <title>Consent for publication</title>
    <p id="Par27">Not applicable.</p>
  </notes>
  <notes id="FPar3" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par28">The authors declare that they have no competing interests in regard to this manuscript.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <mixed-citation publication-type="other">Gliklich RE, Dreyer NA, Leavy MB. Quintiles outcome (Firm), United States. Agency for Healthcare Research and Quality, Effective Health Care Program (U.S.): Registries for evaluating patient outcomes: a user’s guide. In: AHRQ publication no 13(14)-EHC111, 3rd edn. Agency for Healthcare Research and Quality, Rockville, MD; 2014: 1 online resource (2 PDF files (2 volumes)).</mixed-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gillies</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Walton</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Liong</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Arnold</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>McAllister</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Morlet</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Hunyor</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Guymer</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Keeffe</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Essex</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project</article-title>
        <source>Retina</source>
        <year>2014</year>
        <volume>34</volume>
        <issue>1</issue>
        <fpage>188</fpage>
        <lpage>195</lpage>
        <pub-id pub-id-type="doi">10.1097/IAE.0b013e318296b271</pub-id>
        <pub-id pub-id-type="pmid">23836194</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chiang</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Sommer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rich</surname>
            <given-names>WL</given-names>
          </name>
          <name>
            <surname>Lum</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Parke</surname>
            <given-names>DW</given-names>
          </name>
        </person-group>
        <article-title>2nd: The 2016 American Academy of Ophthalmology IRIS((R)) Registry (Intelligent Research in Sight) database: characteristics and methods</article-title>
        <source>Ophthalmology</source>
        <year>2018</year>
        <volume>125</volume>
        <issue>8</issue>
        <fpage>1143</fpage>
        <lpage>1148</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ophtha.2017.12.001</pub-id>
        <pub-id pub-id-type="pmid">29342435</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lundstrom</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Manning</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Barry</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Stenevi</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Henry</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Rosen</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>The European registry of quality outcomes for cataract and refractive surgery (EUREQUO): a database study of trends in volumes, surgical techniques and outcomes of refractive surgery</article-title>
        <source>Eye Vis (Lond)</source>
        <year>2015</year>
        <volume>2</volume>
        <fpage>8</fpage>
        <pub-id pub-id-type="doi">10.1186/s40662-015-0019-1</pub-id>
        <pub-id pub-id-type="pmid">26613089</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lum</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Schachat</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Jampel</surname>
            <given-names>HD</given-names>
          </name>
        </person-group>
        <article-title>The development and demise of a cataract surgery database</article-title>
        <source>Jt Comm J Qual Improv</source>
        <year>2002</year>
        <volume>28</volume>
        <issue>3</issue>
        <fpage>108</fpage>
        <lpage>114</lpage>
        <pub-id pub-id-type="pmid">11902025</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>JCK</given-names>
          </name>
          <name>
            <surname>Ferdi</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Gillies</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Watson</surname>
            <given-names>SL</given-names>
          </name>
        </person-group>
        <article-title>Clinical registries in ophthalmology</article-title>
        <source>Ophthalmology</source>
        <year>2019</year>
        <volume>126</volume>
        <issue>5</issue>
        <fpage>655</fpage>
        <lpage>662</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ophtha.2018.12.030</pub-id>
        <pub-id pub-id-type="pmid">30572076</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Boulanger</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Schlemmer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rossov</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Seebald</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gavin</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Establishing patient registries for rare diseases: rationale and challenges</article-title>
        <source>Pharmaceut Med.</source>
        <year>2020</year>
        <volume>34</volume>
        <issue>3</issue>
        <fpage>185</fpage>
        <lpage>190</lpage>
        <pub-id pub-id-type="doi">10.1007/s40290-020-00332-1</pub-id>
        <pub-id pub-id-type="pmid">32215853</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Broadgate</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Downes</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Halford</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Unravelling the genetics of inherited retinal dystrophies: past, present and future</article-title>
        <source>Prog Retin Eye Res</source>
        <year>2017</year>
        <volume>59</volume>
        <fpage>53</fpage>
        <lpage>96</lpage>
        <pub-id pub-id-type="doi">10.1016/j.preteyeres.2017.03.003</pub-id>
        <pub-id pub-id-type="pmid">28363849</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sharon</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ben-Yosef</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Goldenberg-Cohen</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Pras</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gradstein</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Soudry</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mezer</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Zur</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Abbasi</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Zeitz</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A nationwide genetic analysis of inherited retinal diseases in Israel as assessed by the Israeli inherited retinal disease consortium (IIRDC)</article-title>
        <source>Hum Mutat</source>
        <year>2020</year>
        <volume>41</volume>
        <issue>1</issue>
        <fpage>140</fpage>
        <lpage>149</lpage>
        <pub-id pub-id-type="doi">10.1002/humu.23903</pub-id>
        <pub-id pub-id-type="pmid">31456290</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>FJ</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>JK</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>FY</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Qi</surname>
            <given-names>YH</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>DD</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>LS</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>Q</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Genetic and clinical findings in a large cohort of Chinese patients with suspected retinitis pigmentosa</article-title>
        <source>Ophthalmology</source>
        <year>2019</year>
        <volume>126</volume>
        <fpage>1549</fpage>
        <lpage>1556</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ophtha.2019.04.038</pub-id>
        <pub-id pub-id-type="pmid">31054281</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Holtan</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Selmer</surname>
            <given-names>KK</given-names>
          </name>
          <name>
            <surname>Heimdal</surname>
            <given-names>KR</given-names>
          </name>
          <name>
            <surname>Bragadottir</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Inherited retinal disease in Norway—a characterization of current clinical and genetic knowledge</article-title>
        <source>Acta Ophthalmol</source>
        <year>2020</year>
        <volume>98</volume>
        <issue>3</issue>
        <fpage>286</fpage>
        <lpage>295</lpage>
        <pub-id pub-id-type="doi">10.1111/aos.14218</pub-id>
        <pub-id pub-id-type="pmid">31429209</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Haer-Wigman</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>van Zelst-Stams</surname>
            <given-names>WA</given-names>
          </name>
          <name>
            <surname>Pfundt</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>van den Born</surname>
            <given-names>LI</given-names>
          </name>
          <name>
            <surname>Klaver</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Verheij</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Hoyng</surname>
            <given-names>CB</given-names>
          </name>
          <name>
            <surname>Breuning</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Boon</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Kievit</surname>
            <given-names>AJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Diagnostic exome sequencing in 266 Dutch patients with visual impairment</article-title>
        <source>Eur J Hum Genet</source>
        <year>2017</year>
        <volume>25</volume>
        <issue>5</issue>
        <fpage>591</fpage>
        <lpage>599</lpage>
        <pub-id pub-id-type="doi">10.1038/ejhg.2017.9</pub-id>
        <pub-id pub-id-type="pmid">28224992</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Patel</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Alkuraya</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Alzahrani</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Nowailaty</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Seidahmed</surname>
            <given-names>MZ</given-names>
          </name>
          <name>
            <surname>Alhemidan</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ben-Omran</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Ghazi</surname>
            <given-names>NG</given-names>
          </name>
          <name>
            <surname>Al-Aqeel</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Al-Owain</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mutations in known disease genes account for the majority of autosomal recessive retinal dystrophies</article-title>
        <source>Clin Genet</source>
        <year>2018</year>
        <volume>94</volume>
        <issue>6</issue>
        <fpage>554</fpage>
        <lpage>563</lpage>
        <pub-id pub-id-type="doi">10.1111/cge.13426</pub-id>
        <pub-id pub-id-type="pmid">30054919</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Joo</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Seong</surname>
            <given-names>MW</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>KH</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Woo</surname>
            <given-names>SJ</given-names>
          </name>
        </person-group>
        <article-title>Genetic mutation profiles in Korean patients with inherited retinal diseases</article-title>
        <source>J Korean Med Sci</source>
        <year>2019</year>
        <volume>34</volume>
        <issue>21</issue>
        <fpage>e161</fpage>
        <pub-id pub-id-type="doi">10.3346/jkms.2019.34.e161</pub-id>
        <pub-id pub-id-type="pmid">31144483</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Motta</surname>
            <given-names>FL</given-names>
          </name>
          <name>
            <surname>Martin</surname>
            <given-names>RP</given-names>
          </name>
          <name>
            <surname>Filippelli-Silva</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Salles</surname>
            <given-names>MV</given-names>
          </name>
          <name>
            <surname>Sallum</surname>
            <given-names>JMF</given-names>
          </name>
        </person-group>
        <article-title>Relative frequency of inherited retinal dystrophies in Brazil</article-title>
        <source>Sci Rep</source>
        <year>2018</year>
        <volume>8</volume>
        <issue>1</issue>
        <fpage>15939</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-018-34380-0</pub-id>
        <pub-id pub-id-type="pmid">30374144</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Stone</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Andorf</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Whitmore</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>DeLuca</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Giacalone</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Streb</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Braun</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Mullins</surname>
            <given-names>RF</given-names>
          </name>
          <name>
            <surname>Scheetz</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Sheffield</surname>
            <given-names>VC</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease</article-title>
        <source>Ophthalmology</source>
        <year>2017</year>
        <volume>124</volume>
        <issue>9</issue>
        <fpage>1314</fpage>
        <lpage>1331</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ophtha.2017.04.008</pub-id>
        <pub-id pub-id-type="pmid">28559085</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sergouniotis</surname>
            <given-names>PI</given-names>
          </name>
          <name>
            <surname>Maxime</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Leroux</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Olry</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Rath</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>Dollfus</surname>
            <given-names>H</given-names>
          </name>
        </person-group>
        <article-title>Group E-EOS: an ontological foundation for ocular phenotypes and rare eye diseases</article-title>
        <source>Orphanet J Rare Dis</source>
        <year>2019</year>
        <volume>14</volume>
        <issue>1</issue>
        <fpage>8</fpage>
        <pub-id pub-id-type="doi">10.1186/s13023-018-0980-6</pub-id>
        <pub-id pub-id-type="pmid">30626441</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wilkinson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Dumontier</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Aalbersberg</surname>
            <given-names>IJ</given-names>
          </name>
          <name>
            <surname>Appleton</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Axton</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Baak</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Blomberg</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Boiten</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>da Silva Santos</surname>
            <given-names>LB</given-names>
          </name>
          <name>
            <surname>Bourne</surname>
            <given-names>PE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The FAIR Guiding Principles for scientific data management and stewardship</article-title>
        <source>Sci Data</source>
        <year>2016</year>
        <volume>3</volume>
        <fpage>160018</fpage>
        <pub-id pub-id-type="doi">10.1038/sdata.2016.18</pub-id>
        <pub-id pub-id-type="pmid">26978244</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bellgard</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Render</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Radochonski</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hunter</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Second generation registry framework</article-title>
        <source>Source Code Biol Med</source>
        <year>2014</year>
        <volume>9</volume>
        <fpage>14</fpage>
        <pub-id pub-id-type="doi">10.1186/1751-0473-9-14</pub-id>
        <pub-id pub-id-type="pmid">24982690</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kodra</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>de la Paz</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>Coi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Santoro</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bianchi</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Ahmed</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Rubinstein</surname>
            <given-names>YR</given-names>
          </name>
          <name>
            <surname>Weinbach</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Taruscio</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Data quality in rare diseases registries</article-title>
        <source>Adv Exp Med Biol</source>
        <year>2017</year>
        <volume>1031</volume>
        <fpage>149</fpage>
        <lpage>164</lpage>
        <pub-id pub-id-type="doi">10.1007/978-3-319-67144-4_8</pub-id>
        <pub-id pub-id-type="pmid">29214570</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sernadela</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gonzalez-Castro</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Carta</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>van der Horst</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Lopes</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kaliyaperumal</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Thompson</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Queralt-Rosinach</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Lopez</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Linked registries: connecting rare diseases patient registries through a semantic web layer</article-title>
        <source>Biomed Res Int</source>
        <year>2017</year>
        <volume>2017</volume>
        <fpage>8327980</fpage>
        <pub-id pub-id-type="doi">10.1155/2017/8327980</pub-id>
        <pub-id pub-id-type="pmid">29214177</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Read-Brown</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hribar</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Reznick</surname>
            <given-names>LG</given-names>
          </name>
          <name>
            <surname>Lombardi</surname>
            <given-names>LH</given-names>
          </name>
          <name>
            <surname>Parikh</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Chamberlain</surname>
            <given-names>WD</given-names>
          </name>
          <name>
            <surname>Bailey</surname>
            <given-names>ST</given-names>
          </name>
          <name>
            <surname>Wallace</surname>
            <given-names>JB</given-names>
          </name>
          <name>
            <surname>Yackel</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Chiang</surname>
            <given-names>MF</given-names>
          </name>
        </person-group>
        <article-title>Time requirements for electronic health record use in an academic ophthalmology center</article-title>
        <source>JAMA Ophthalmol</source>
        <year>2017</year>
        <volume>135</volume>
        <issue>11</issue>
        <fpage>1250</fpage>
        <lpage>1257</lpage>
        <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2017.4187</pub-id>
        <pub-id pub-id-type="pmid">29049512</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sinsky</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Colligan</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Prgomet</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Reynolds</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Goeders</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Westbrook</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Tutty</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Blike</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Allocation of physician time in ambulatory practice: a time and motion study in 4 specialties</article-title>
        <source>Ann Intern Med</source>
        <year>2016</year>
        <volume>165</volume>
        <issue>11</issue>
        <fpage>753</fpage>
        <lpage>760</lpage>
        <pub-id pub-id-type="doi">10.7326/M16-0961</pub-id>
        <pub-id pub-id-type="pmid">27595430</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
